NIH-funded research R15 grant

Understanding how specific mutations in a protein affect ovarian cancer

Official title: Impact of pathogenic missense mutations on the ARID domain of ARID1a

Funded at Clemson University · NIH-10654137 · Data updated 2026-11-12

This study is looking at how certain changes in the ARID1a protein might affect its job in keeping cells healthy, which could help us understand more about how ovarian cancer develops and lead to better treatments for patients.

Quick facts

Grant typeR15 grant
Study typeNIH-funded research
Funding institutionClemson University
NIH-funded
Lab location1 site (Clemson, United States)
Project startApril 12, 2023
Project endMarch 31, 2026
Funding year2023
Award (this year)$443,128
NIH project number1R15CA280699-01
Project IDNIH-10654137 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals diagnosed with ovarian cancer, particularly those with known ARID1a mutations.

Less likely to help

Patients without ovarian cancer or those whose tumors do not involve ARID1a mutations may not benefit from this research.

What this research studies

This research investigates the effects of pathogenic missense mutations in the ARID1a protein, which plays a crucial role in regulating gene activity and maintaining cell health. By analyzing how these mutations impact the protein's stability and its ability to bind DNA, the research aims to uncover the subtle mechanisms that contribute to ovarian cancer development. The approach involves detailed modeling and bioinformatics techniques to predict the consequences of these mutations on cellular functions. Ultimately, this work seeks to provide insights that could lead to improved understanding and treatment options for ovarian cancer patients.

Why it matters

Potential benefit: If successful, this research could lead to better diagnostic tools and targeted therapies for ovarian cancer patients.

How similar studies have gone: Previous research has shown that understanding mutations in tumor suppressor genes can lead to significant advancements in cancer treatment, suggesting this approach has potential for success.

Where this research is happening

  • Clemson University
    Clemson, United States
    Active

Researchers

  • Principal investigator: Sanabria, Hugo — Clemson University
  • Study coordinator: Sanabria, Hugo

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.